Universal Diagnostics Olympus
1 known investors
Universal DX develops blood-based tests for early cancer detection, with a focus on colorectal cancer screening. The company runs clinical studies through a network of hospitals and gastrointestinal clinical teams across the U.S. and Europe.
Also known as Universal DX
Investors · 1
Company profile
researched Aug 2026Universal DX (Universal Diagnostics) is developing blood tests intended to detect cancer at early stages, with the stated aim of making cancer preventable and curable. The company describes a technology platform built on disease biology that is designed to "read" the signal of cancer in blood, applied initially to high-burden gastrointestinal cancers.
Its lead product is Signal-C, a liquid biopsy test for the detection of colorectal cancer and advanced adenomas. The company reports that Signal-C detects colorectal cancer with 92% sensitivity and 94% specificity. Universal DX also presents development results at scientific conferences and congresses, framing engagement with the clinical and scientific community as part of its product development approach.
Business model
The company develops proprietary blood-based cancer screening tests. It has described a strategic collaboration under which Signal-C would be made available through the Quest Diagnostics laboratory network in the United States following FDA approval, expanding access to screening.
Latest developments
The company has announced a strategic collaboration with Quest Diagnostics intended to make the Signal-C blood test available through Quest's network in the U.S. after FDA approval.
▸Full profile — market position, technology, go-to-market
Market position
Positioned in blood-based early cancer detection (liquid biopsy), with an initial focus on colorectal cancer and advanced adenoma detection.
Technology
Universal DX combines multi-omics analysis, computational biology and machine learning to identify cancer signals circulating in blood. The platform is positioned as disease-knowledge-driven and is first being applied to gastrointestinal cancers.
Go-to-market
Distribution through a strategic collaboration with Quest Diagnostics, which would offer the Signal-C blood test across its U.S. network after FDA approval, alongside dissemination of clinical results at scientific conferences.
Populations eligible for colorectal cancer screening in the United States, reached via clinical laboratory testing networks.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsUniversal DX announced a strategic collaboration with Quest Diagnostics under which the Signal-C blood-based colorectal cancer test would be available through the Quest Diagnostics network in the U.S. following FDA approval.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- Universal Diagnostics Olympusuniversaldx.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Universal Diagnostics Olympus do?
- Universal DX develops blood-based liquid biopsy tests for early detection of colorectal cancer and advanced adenomas.
- Who are Universal Diagnostics Olympus's investors?
- Universal Diagnostics Olympus's investors include Cerity Partners Ventures.